ArticleJAC-antimicrobial resistance2025
Efficacy of high-dose tigecycline-containing regimens for the combination treatment of carbapenem-resistant Enterobacterales bacteraemia.
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Enterobacterales (CRE) are critical priority pathogens due to limited therapeutic options. Standard-dose tigecycline (100 mg/day) may not achieve adequate plasma levels for treating CRE bacteraemia. High-dose tigecycline (HD-TGC; 200 mg/day) may improve drug exposure and clinical outcomes, though supporting evidence remains limited. This study aimed to evaluate the efficacy of an HD-TGC-containing regimen compared with other treatments for CRE bacteraemia. Methods: We conducted a retrospective propensity-score matched study at Phramongkutklao Hospital in Bangkok, Thailand, including adults with monomicrobial CRE bacteraemia (2017-2021). The primary outcome was 30-day all-cause mortality. Secondary outcomes were clinical and microbiological responses on Day 7. Results: Of 161 eligible patients, 37 (23.0%) received HD-TGC and 124 received other regimens. Conclusions: HD-TGC was associated with improved microbiological clearance and showed a trend towards reduced mortality in patients with CRE bacteraemia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.